LA
ESPR

Lee Ainslie’s Esperion Therapeutics ESPR Stock Holding History

Lee Ainslie’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-49,973
Closed -$602K – 424
2021
Q3 		$602K Buy
49,973
+4,981
+11% +$72.5K 0.01% 416
2021
Q2 		$952K Buy
+44,992
New +$1.08M 0.01% 317

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Lee Ainslie's ESPR Position: Q4 2021 in Review

Lee Ainslie sold out of Esperion Therapeutics (ESPR) in Q4 2021, closing a stake of 49,973 shares — an estimated $602K sold.

Lee Ainslie first reported a position in ESPR in Q2 2021 and held it in 2 quarters. The position peaked at $952K in Q2 2021. 133 funds tracked by Wall St. Rank hold ESPR as of Q4 2021.

  • Lee Ainslie reported no remaining Esperion Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Lee Ainslie sold 49,973 Esperion Therapeutics shares in Q4 2021, an estimated $602K.
  • Lee Ainslie first reported a position in Esperion Therapeutics in Q2 2021 and held it in 2 quarters.
  • Lee Ainslie's Esperion Therapeutics position peaked at $952K in Q2 2021.
  • 133 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2021.

Based on Maverick Capital's 13F filing for Q4 2021, filed 14 Feb 2022.